Scaling advocacy beyond the bedside
For clinicians interested in advocacy, Dr. Valley offers a reassuring perspective: The foundation already exists.
“We are natural advocates,” he said. “That’s what we do at the bedside.”
The challenge—and the opportunity—is to extend that mindset beyond individual patients.
“Instead of just fixing a problem for one patient at a time, we should ask: Are there opportunities to scale this? Can we work together to create change at a larger level?”
In the case of pulse oximetry, that has meant engaging with regulatory agencies, raising awareness across the medical community, and pushing for improved device standards.
Dr. Valley and his colleagues began by publishing their findings and bringing attention to the issue, then they worked to ensure the data reached the right audiences. Their efforts have contributed to increased awareness and have helped prompt engagement from organizations such as the US Food and Drug Administration, though progress has been uneven.
“We’ve had varying degrees of success,” he said, noting that while some institutions have responded, discernible change at a systemwide level takes time.
There is growing recognition of the problem and momentum toward better standards, but reliable solutions are not yet fully in place. Clinicians are left navigating this uncertainty in real time, balancing the benefits of pulse oximetry with a clearer understanding of its limitations.
“I’m still taking care of patients in the ICU, and I still don’t really know what to do about pulse oximeters,” he admitted.